Kairos Pharma (KAPA) vs VivoSim Labs (VIVS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
VivoSim Labs is the larger company by market cap ($3.0 million vs $2.7 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | KAPA | VIVS |
|---|---|---|
| Share price | $0.8103 | $0.1801 |
| Market cap | $2.74M | $2.99M |
| 1-day change | -15.55% | +1.64% |
| EPS (TTM) | $-1.96 | $-4.47 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $9.24 | $3.41 |
| 52-week low | $0.7827 | $0.1681 |
| Distance from 52-week high | -91.23% | -94.72% |
| Analyst consensus | none | — |
| Avg. price target upside | +5947.14% | — |
| Average volume | 602.89K | 5.85M |
| Shares outstanding | 3.39M | 16.59M |
| Employees | 1 | 15 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Kairos Pharma
KAPA stock →Kairos Pharma, Ltd., a clinical-stage biopharmaceutical company, develops immunotherapy and cell therapies for the treatment of cancer. The company offers therapeutics, including antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma.
Health Care · Biotechnology: Pharmaceutical Preparations · 1 employees
About VivoSim Labs
VIVS stock →VivoSim Labs, Inc., a pharmaceutical and biotechnology services company, provides testing of drugs and drug candidates in three-dimensional (3D) human tissue models of liver and intestine. It offers partners liver and intestinal toxicology insights through its new approach methodologies (NAM) models.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 15 employees
KAPA vs VIVS FAQ
Which is bigger, Kairos Pharma or VivoSim Labs?
VivoSim Labs (VIVS) is larger, with a market capitalization of $2.99M compared with $2.74M for Kairos Pharma (KAPA).
Are Kairos Pharma and VivoSim Labs in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for Kairos Pharma and Biotechnology: Biological Products (No Diagnostic Substances) for VivoSim Labs.